Effect of different local and systemic therapy upon urinary bladder cytology

Area of Science:

• Uro-oncology
• Cytopathology
• Medical Oncology

Background:

• Urothelial bladder carcinoma requires effective treatment and monitoring.
• Intravesical chemotherapy and combined radiotherapy-chemotherapy are used for bladder cancer.
• Cytological analysis of urine and bladder washings is vital for follow-up.

Purpose of the Study:

• To evaluate the cytological effects of intravesical mitomycin C and thiotepa, and integrated radiotherapy-chemotherapy.
• To determine if these therapies alter nuclear DNA content.
• To assess the utility of urinary cytology in detecting bladder carcinoma recurrence post-treatment.

Main Methods:

• Performed 1,900 cytological analyses on 127 patients with urothelial bladder carcinomas.
• Patients received transurethral resection followed by intravesical mitomycin C or thiotepa.
• A subset received integrated radiotherapy and chemotherapy for locally advanced disease.
• Utilized single-cell spectrocytophotometry for DNA measurements.

Main Results:

• Intravesical and integrated therapies induced cytological effects that could be misinterpreted.
• These treatment-induced effects did not correlate with increased nuclear DNA content.
• Urinary cytology can detect bladder carcinoma recurrences when interpreted by experienced professionals, considering treatment effects.

Conclusions:

• Knowledge of treatment-induced cytological effects is mandatory for accurate urinary cytology interpretation.
• Early detection of bladder carcinoma recurrence is possible with experienced cytopathologists/urologists.
• Systemic cyclophosphamide and immunosuppressive therapy also alter urinary cytology.